Eli Lilly Dominates U.S. Obesity Market Share
Eli Lilly held a commanding 60.9% share of the U.S. obesity and diabetes drug market in the second quarter, according to CNBC‘s earnings presentation. In comparison, rival Novo Nordisk held a 38.8% share during the same period. The performance underscores a widening divide in Wall Street’s confidence between the two obesity drug leaders, even as … Read more